ReviewBiomolecules2026
Hepatocyte-Derived Apoptotic Bodies as Pathological Intercellular Messengers in the Liver.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathophysiological mechanisms of cell death affecting graft survival in liver transplantation.World journal of transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatocyte apoptotic bodies (ApopBDs) are extracellular vesicles formed during hepatocyte apoptosis. Although they were initially recognized as cellular waste and vesicles that clear toxic substances and viral infections in the liver, they are now known to serve as key mediators of intercellular communication that influence key metabolic and immune responses, such as inflammation, regeneration, and fibrosis. While numerous functions of ApopBDs in the liver are emerging, this review will focus on discussing their biogenesis, characterization, and roles in different liver diseases, with an emphasis on intercellular communication with liver-resident cells. The mechanisms of liver injury are convoluted by series of injurious crosstalk between hepatocyte ApopBDs and surviving resident cells. A unique feature of liver injury is a constant cycle of hepatocyte apoptosis, which has been attributed to crosstalk between surviving hepatocytes and their ApopBDs. The progression of liver injury is also affected by the activation of proinflammatory and profibrotic pathways such as TLR9/NLRP3 and JAK-STAT3. Given the expression of hepatocyte-specific molecular signatures on these ApopBDs, their application as diagnostic tools may improve the treatment of liver diseases. Although the science of hepatocyte ApopBDs is fairly recent and still emerging, in-depth understanding of this aspect of liver biology may provide a novel therapeutic option for the progression of liver damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.